We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.18% | 28.00 | 27.50 | 28.10 | 27.95 | 27.80 | 27.95 | 805,775 | 16:35:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 48.48M | -776k | -0.0011 | -252.73 | 187.67M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/3/2024 17:33 | 'yet another'? Could you list the others so we can see what they all are? On the tly thread where it belongs please. 'dismayed'? Generally indifferent I'm afraid, but amused by tly's 'progress' over the last couple of years :¬) | supernumerary | |
11/3/2024 16:14 | Dan/Supernumerary, I see TLY won yet another contract. ;-) Added to the increase in institution holding last week. You, 1gw and his mates must be really dismayed. 1gw and his mates lost 95% (and still falling) on Byot. Also: Nexn, ex blnx, ex trmr, ex rthm... so many iterations of blnx. The gang have lost 80-90% on every iteration of blnx and it's still falling. Nano down 60& Stu bust. I wonder if 1gw or you will post a graph showing the appalling share price movements of Byot, Nexn, Trmr, Nano... Maybe compare them to my EZJ, MKS ramps. ;-) ;-) | sikhthetech | |
11/3/2024 13:19 | Trading range 25-28p? Actually consolidation might be a good thing. | chica1 | |
11/3/2024 00:06 | One day some company we invest in will create AI trolls. Then we're totally screwed lol | hsduk101 | |
10/3/2024 21:41 | Poor old tikhy - I'm not surprised they grey his posts out :¬( Thanks advfn :¬) | supernumerary | |
10/3/2024 20:32 | Tipped by Midas in the Daily Mail today as one of "the Great British businesses that lead the world": "The life scientific The UK is recognised the world over for its prowess in life sciences from discovering new drugs and developing vaccines to producing advanced medical kit. Last week, the Chancellor highlighted his commitment to this sector, with funds and strategic support. Hunt is not alone in backing British biomedical brains. As he delivered his Budget, AstraZeneca announced a £650 million investment in the UK to bolster scientific skills and help develop new vaccines. This shot in the arm should filter down to a host of smaller life sciences firms. HVivo, for instance, has developed trail-blazing trials for vaccines, helping to bring them to market faster and so saving lives. Its shares have soared from 10p to 27p since Midas recommended them in January last year, but the stock should continue to deliver. Boss Mo Khan works with some of the world's biggest drug firms and HVivo has also helped develop vaccines for respiratory syncytial virus (RSV), the bug that swept the US and UK last winter and can be fatal for infants and the elderly." | manc10 | |
10/3/2024 19:46 | Read the company newsflow. FACTS: The founder/Chairman dumped majority of his holdings recently: Growth slow significantly Fy2022: £48.5m (+30%) Fy2023: £56m (+15.5%) Fy2024: £62m(+10.7%) "Full year revenue of £56.0 million, an increase of 15.5% (2022: £48.5 million) Revenue guidance of £62 million for 2024" Huge >7m options to CEO: Look at the options awarded to the CEO, less than a year ago, exercisable in a year and the conditions attached. These and the number of shares bought by him, tells you why the company is being talked up. "The LTIP has been designed to reward, incentivise and retainMr Khan to deliver sustainable growth for shareholders. The deemed date of award is 24 February 2022, which is the date Mr Khan was appointed CEO. Under the LTIP,Mr Khan has been awarded 7,227,273 nominal cost long term incentive options ("LTIP Options " ) over ordinary shares of £0.001 each in the Company. Vesting of the LTIP Options is conditional upon a three-year total shareholder return ("TSR") performance against an initial 11p reference price. A portion of the LTIP Options will vest on the third anniversary of the date of award subject to the achievement of a minimum 10% CAGR TSR performance increasing on a straight-line basis to vesting in full subject to the achievement of a 22.5% CAGR TSR performance. hxxps://polaris.brig Add to questionable business model. No evidence of significant buying/holding by InstitutionS. | sikhthetech | |
10/3/2024 19:43 | DON'T FEED THE TROLLS IT ONLY ENCOURAGES THEM!! | bb cleaner | |
10/3/2024 19:43 | DON'T FEED THE TROLLS IT ONLY ENCOURAGES THEM!! | bb cleaner | |
10/3/2024 19:43 | DON'T FEED THE TROLLS IT ONLY ENCOURAGES THEM!! | bb cleaner | |
10/3/2024 18:58 | Lol you are getting on for 90% down on Totally since some of your bullish posts and you are still bullish, so I can't take you seriously | dan_the_epic | |
10/3/2024 18:53 | Dan, "Don't be a sheep and only follow what directors and institutions do." You mean you'll ramp and change the metrics based on which will entice the gullible in. You were ramping these on institution holdings recently. lol So in your words don't follow directors or institutions but be a sheep and follow media tips. lol Obviously the share price will rise tomorrow morning, as traders come in. So you'll be loading up and not selling a single share until revenues hit £90m, will you? Not like the other pump and dumpers, who have disappeared, eh? Let's look at facts, where I have been negative. Byot - rose on Midas Tip, I bought/sold whilst still maintaining a negative stance throughout BASED ON COMPANY NEWSFLOW. I sold at 8p, whilst 1gw and his mates continued to ramp. Anyone who followed 1gw and his mates would be down 95% on Byot Trmr - rose on ad tech bubble. I bought/sold whilst maintaining a negative stance throughout BASED ON COMPANY NEWSFLOW. 1gw and his mates with multiple ids continued to ramp at 800p++ Anyone who followed 1gw and his mates and not the company newsflow would be down 80%. Then we also have NANO. Down 60% etc etc etc I'm glad I followed my own conviction, read the company newsflow and facts and not media or anonymous posters. Funny how you don't have an opinion on the serial failure 1gw and mates???? ;-) | sikhthetech | |
10/3/2024 18:09 | I'd rather own a stock that is flying with excellent fundamentals, oodles of cash, cash generation and high margins. Rather than a business which barely had a balance sheet to stand on, that is down well over 80% since you started pumping it. Delulu investor mindset. Make your own decisions. Don't just follow Director and institution buys and sells like a lemming. Make your OWN mind up. Have your OWN conviction. Don't be a sheep and only follow what directors and institutions do. There is no evidence to say that is remotely a profitable strategy. For those who missed it, the Midas column tipped Hvivo this weekend so Sikh is panicking because the stock is going to be up again tomorrow 😂 | dan_the_epic | |
10/3/2024 17:18 | You, 1gw and his mates must be dismayed that YET ANOTHER Institution declared > 5% in TLY only 2 trading days ago. :-) How's that compare against the paltry 1-2% institution declarations in HVO. The fact is HVO's chairman/founder dumped majority of his holding whilst 1gw and his mates continued to ramp at 30p. The fact is growth has slowed significantly, as evidenced by company statements. Do you think the Chairman/Founder thought it best to dump majority of his holding because of the slowdown??? | sikhthetech | |
10/3/2024 15:02 | Chica "There was value in buying back shares when I said they.should.Remember Dutch Auction! That was about10-12p if I remember correctly,not so much now" Absolutely. I've traded these before but wouldn't buy them at current levels, especially now the Chairman/Founder has dumped the majority of his holding. That is a red flag for me. The newsflow/events have been as predicted. sikhthetech14 Feb '24 - 13:49 - 6589 of 6956 0 1 0 There you go, as predicted, this was repeatedly talked up. CF selling significant number, as he is now in profit. Why would he sell if there was significant growth ahead. sikhthetech - 04 Feb 2024 - 21:49:25 - 6386 of 6586 Whenever there's huge options awarded to 1 director then I see it as a red flag. A similar happened at RTHM, which I also saw as a red flag, whilst 1gw and his mates were ramping them, even at the peak. The shares crashed 80%. | sikhthetech | |
10/3/2024 14:51 | There was value in buying back shares when I said they.should.Remember Dutch Auction! That was about10-12p if I remember correctly,not so much now A £500k buyback would have a minimal effect on the shares count and earning per share | chica1 | |
10/3/2024 14:40 | Groundhog day ! | yump | |
10/3/2024 13:53 | Tipped by Midas in the Daily Mail today as one of "the Great British businesses that lead the world": "The life scientific The UK is recognised the world over for its prowess in life sciences from discovering new drugs and developing vaccines to producing advanced medical kit. Last week, the Chancellor highlighted his commitment to this sector, with funds and strategic support. Hunt is not alone in backing British biomedical brains. As he delivered his Budget, AstraZeneca announced a £650 million investment in the UK to bolster scientific skills and help develop new vaccines. This shot in the arm should filter down to a host of smaller life sciences firms. HVivo, for instance, has developed trail-blazing trials for vaccines, helping to bring them to market faster and so saving lives. Its shares have soared from 10p to 27p since Midas recommended them in January last year, but the stock should continue to deliver. Boss Mo Khan works with some of the world's biggest drug firms and HVivo has also helped develop vaccines for respiratory syncytial virus (RSV), the bug that swept the US and UK last winter and can be fatal for infants and the elderly." | manc10 | |
10/3/2024 13:36 | There were several media tips early in the year. The newsflow and events have been as predicted. This was/is being talked up so they can sell. The Chairman and founder dumped majority of his holding so soon after it was talked up. The CEO has a huge 7m options, awarded a year ago and exercisable in a year. The revenue growth has slowed significantly. The company has been running for year, yet there's been no evidence of significant holdings/buying by InstitutionS 2021, 2022, 2023. Now it's been talked up and some IIs take tiny holdings 1-2%. Read the company newsflow, it's all there. | sikhthetech | |
10/3/2024 09:30 | Nice one rivaldo 6950. Thanks | 666james | |
10/3/2024 08:08 | Thanks Rivaldo | pgaffney | |
10/3/2024 07:50 | Tipped by Midas in the Daily Mail today as one of "the Great British businesses that lead the world": "The life scientific The UK is recognised the world over for its prowess in life sciences from discovering new drugs and developing vaccines to producing advanced medical kit. Last week, the Chancellor highlighted his commitment to this sector, with funds and strategic support. Hunt is not alone in backing British biomedical brains. As he delivered his Budget, AstraZeneca announced a £650 million investment in the UK to bolster scientific skills and help develop new vaccines. This shot in the arm should filter down to a host of smaller life sciences firms. HVivo, for instance, has developed trail-blazing trials for vaccines, helping to bring them to market faster and so saving lives. Its shares have soared from 10p to 27p since Midas recommended them in January last year, but the stock should continue to deliver. Boss Mo Khan works with some of the world's biggest drug firms and HVivo has also helped develop vaccines for respiratory syncytial virus (RSV), the bug that swept the US and UK last winter and can be fatal for infants and the elderly." | rivaldo | |
08/3/2024 17:50 | I bet you all read the blank spaces ;))) | baldrick1 | |
08/3/2024 15:57 | Ah there it is. Thought it was quiet and then the filter trigger was activated in quick succession. | digger2779 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions